Treatment with ICIs does not generally improve survival of glioblastoma patients, e.g. as shown in a randomized phase 3 clinical trial on the effect of programmed death-1 (PD-1) inhibitor nivolumab versus anti-VEGF antibody bevacizumab in patients with recurrent glioblastoma [62]. The gene discussed is VEGFA; the disease is glioblastoma.